Trials / Withdrawn
WithdrawnNCT04373616
A Study of ACI-24 in Adults With Down Syndrome
A Phase 2 Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability and Target Engagement of ACI-24 in Adults With Down Syndrome
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- AC Immune SA · Industry
- Sex
- All
- Age
- 40 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
This study is a prospective multicenter, placebo-controlled, double-blind, randomized study to assess the effect of one dose ACI-24 versus placebo over a 74-week treatment period and 26-week safety follow-up period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ACI-24 | injections |
| BIOLOGICAL | Placebo | injections |
Timeline
- Start date
- 2021-10-01
- Primary completion
- 2024-04-01
- Completion
- 2024-10-01
- First posted
- 2020-05-04
- Last updated
- 2021-10-22
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04373616. Inclusion in this directory is not an endorsement.